Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Parathyroid Hormone
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Takeda Provides NATPARA Regulatory Update
Details : The CRL indicates that the FDA has completed its review of the NATPARA, is a prescription parathyroid hormone PAS and determined that it cannot be approved in its present form.
Brand Name : Natpara
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 22, 2022
Lead Product(s) : Parathyroid Hormone
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?